Italfarmaco Research

Focus: Italfarmaco Research is a pharmaceutical company based in Cinisello Balsamo, Italy, specializing in pharmaceuticals and fine chemicals with focus on neurology.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Italfarmaco Research

AI assessmentNot Hiring

No open roles listed right now. Follow Italfarmaco Research to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

1 in 5yr

TIGLUTIK KIT

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

RILUZOLE

Amyotrophic Lateral Sclerosis (ALS)

$8M Part D

Post-LOE

Foundational revenue driver representing 95% of company revenue; multiple generic ANDA formulations compete in mature market.

Help build intelligence for Italfarmaco Research

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established player in rare disease (ALS) with multiple marketed formulations generating stable revenue from a well-characterized mechanism
Geographic advantage in Italy/Europe with specialty pharma focus on neurology and muscular dystrophy
Diversification into DUVYZAT (givinostat) for Duchenne Muscular Dystrophy represents pipeline expansion beyond riluzole dependence

Watch Out For

Extreme revenue concentration (95% from single drug riluzole) creates significant business continuity risk and limits career growth diversity
Minimal active hiring (0 open positions) and minimal pipeline activity (1 observational trial only) suggest limited expansion and advancement opportunities
Multiple riluzole formulations already post-LOE with active drug shortage, indicating market maturity and potential competitive/supply pressures

Generated by Claude from Italfarmaco Research's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

EXSERVAN

Amyotrophic Lateral Sclerosis (ALS)

$409K Part D

Peak

Branded oral suspension formulation at peak lifecycle; significantly lower revenue than generic RILUZOLE suggests market limitations.

TIGLUTIK KIT

Amyotrophic Lateral Sclerosis (ALS)

LOE Approaching2.9yr

Enteral suspension formulation facing patent cliff in 2029; LOE date approaching within 5 years will impact future revenue.

DUVYZAT

Duchenne Muscular Dystrophy

Growth10.5yr